Description

Simple

A medication used to treat certain types of leukemia (blood cancers).

Clinical

An anthracycline aminoglycoside used to induce remission of nonlymphocytic leukemia and acute lymphocytic leukemia.

Overview

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.

Pharmacology

Indication

For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Pharmacodynamic

Daunorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most o... Read more

Mechanism of action

Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation porti... Read more

Absorption

Information currently not available.

Protein binding

97% binding-albumin

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

18.5 hours

Route of elimination

Twenty-five percent of an administered dose of daunorubicin hydrochloride is eliminated in an active form by urinary excretion and an estimated 40% by biliary excretion.

Toxicity

LD50=20 mg/kg (mice, IV); LD50=13 mg/kg (rat, IV)

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Daunorubicin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The serum concentration of (R)-warfarin can be increased when it is combined with Daunorubicin.
(S)-Warfarin
The serum concentration of (S)-Warfarin can be increased when it is combined with Daunorubicin.
2-Methoxyethanol
The risk or severity of adverse effects can be increased when Daunorubicin is combined with 2-Methoxyethanol.
4-hydroxycoumarin
The metabolism of 4-hydroxycoumarin can be decreased when combined with Daunorubicin.
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when Daunorubicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
9-aminocamptothecin
The metabolism of 9-aminocamptothecin can be decreased when combined with Daunorubicin.
Abatacept
The risk or severity of adverse effects can be increased when Daunorubicin is combined with Abatacept.
Abciximab
The risk or severity of bleeding can be increased when Abciximab is combined with Daunorubicin.
Abemaciclib
The serum concentration of Abemaciclib can be increased when it is combined with Daunorubicin.
Abetimus
The risk or severity of adverse effects can be increased when Daunorubicin is combined with Abetimus.
Acebutolol
The serum concentration of Acebutolol can be increased when it is combined with Daunorubicin.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Daunorubicin.
Acetaminophen
The serum concentration of Daunorubicin can be increased when it is combined with Acetaminophen.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Daunorubicin.
Acetyldigoxin
Daunorubicin may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.
Acetylsalicylic acid
The serum concentration of Acetylsalicylic acid can be increased when it is combined with Daunorubicin.
Acteoside
The risk or severity of adverse effects can be increased when Daunorubicin is combined with Acteoside.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Daunorubicin.
Adenovirus type 7 vaccine live
The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Daunorubicin.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Daunorubicin.